Glucagon-like peptide-1 (GLP-1) is a 30- or 31-amino-acid-long peptide hormone deriving from tissue-specific posttranslational processing of the proglucagon peptide.Glucagon-like peptide-1 receptor agonists gained approval as drugs to treat diabetes and obesity starting in the 2000s.
If your patients are taking GLP-1s, youve explained the common side effects, such as gastrointestinal (GI) issues and muscle-loss implications. However, GLP-1 receptor agonists, often prescribed for type 2 diabetes and sometimes for weight management, can affect the entire body including the oral cavity, said Anita Aminoshariae, DDS, MS, professor in the Department of Endodontics and ...
Learn how GLP-1 receptor agonists like semaglutide and tirzepatide affect oral health. Discover risks, signs, and dental care strategies.
Methods A narrative review of the medical and dental literature was undertaken, alongside review of UK regulatory guidance, to assess the effects of GLP-1 receptor agonists on oral and facial tissues.
dvances in treatment, such as glucagon-like peptide 1 receptor agonists (GLP-1RAs), have led to better glycemic control and may reduce T2DM-related complications, highlighting their potential in addressing interconnected oral-systemic health challenges.
This particular example perfectly highlights why Glp-1 Receptor Agonist And Dental Health is so captivating.
Simple Summary This study explores how semaglutide, a drug extensively and widely used to treat diabetes and obesity, may cause oral side effects, such as dry mouth, by affecting salivary gland function. Based on the available data, we propose that different GLP-1 receptor agonists activate the salivary gland receptor in distinct ways, triggering pathways that regulate secretion and cell ...
GLP-1 receptor agonists in type 2 diabetes management: Current perspectives.The effect of GLP-1 receptor agonists on metabolic profile in patients with obesity and type 2 diabetes. Public Health and Management, 22(1), 103109.
Dental and oral health fact check.Researchers also suggested that GLP-1 receptor agonists may offer a promising therapeutic approach, as they have the potential to address both obesity and alcohol use disorder simultaneously.
